PE20160556A1 - Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos - Google Patents

Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos

Info

Publication number
PE20160556A1
PE20160556A1 PE2016000010A PE2016000010A PE20160556A1 PE 20160556 A1 PE20160556 A1 PE 20160556A1 PE 2016000010 A PE2016000010 A PE 2016000010A PE 2016000010 A PE2016000010 A PE 2016000010A PE 20160556 A1 PE20160556 A1 PE 20160556A1
Authority
PE
Peru
Prior art keywords
methods
compositions
dihydroxyphenyl
compounds
neurotransmitter
Prior art date
Application number
PE2016000010A
Other languages
English (en)
Inventor
Courtney Holmes
Rudolf-Geisbert Alken
Chengzhi Zhang
David S Goldstein
Original Assignee
Auspex Pharmaceuticals Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc, Us Health filed Critical Auspex Pharmaceuticals Inc
Publication of PE20160556A1 publication Critical patent/PE20160556A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

La presente invencion se relaciona a compuestos de formula I que actuan como neurotransmisores, composiciones farmaceuticas de los mismos y metodos de uso de los mismo, donde R1 y R2 son hidrogeno, metilo, etc; R3-R8 son hidrogeno o deuterio; R9-R11 son hidrogeno, metilo, etc. Por lo menos uno de R3-R6 y R8 es deuterio. Son compuestos preferidos los compuestos de estructura (i), (ii) entre otros
PE2016000010A 2013-07-08 2014-07-08 Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos PE20160556A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361843549P 2013-07-08 2013-07-08
US201462010098P 2014-06-10 2014-06-10

Publications (1)

Publication Number Publication Date
PE20160556A1 true PE20160556A1 (es) 2016-06-11

Family

ID=52133230

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000010A PE20160556A1 (es) 2013-07-08 2014-07-08 Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos

Country Status (16)

Country Link
US (5) US20150011630A1 (es)
EP (2) EP3019467A4 (es)
JP (1) JP6567515B2 (es)
KR (1) KR20160041912A (es)
CN (1) CN105473545B (es)
AU (2) AU2014287418A1 (es)
BR (1) BR112016000338A8 (es)
CA (1) CA2917159C (es)
CL (1) CL2016000019A1 (es)
EA (1) EA201600093A1 (es)
HK (2) HK1216747A1 (es)
IL (2) IL243488A0 (es)
MX (1) MX2016000219A (es)
PE (1) PE20160556A1 (es)
SG (2) SG11201510764QA (es)
WO (1) WO2015006315A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109640989A (zh) * 2016-08-30 2019-04-16 施万生物制药研发Ip有限责任公司 用于治疗神经性起立性低血压的化合物
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020212948A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
CA3153305A1 (en) * 2019-10-25 2021-04-29 Anthony P. FORD Methods for treating neurological disorders with ?1a-ar partial agonists
WO2021247963A1 (en) * 2020-06-05 2021-12-09 Senda Biosciences, Inc. (s)-alpha-fluoromethyltyrosine as decarboxylase inhibitors for use in the treatment of hypotension

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3360726D1 (en) * 1982-01-14 1985-10-17 Sumitomo Chemical Co Process for producing threo-3-(3,4-dihydroxyphenyl)serine
CA1223602A (en) 1983-05-25 1987-06-30 Naohito Ohashi Process for producing 3-(3,4-dihydroxyphenyl) serine
JP3764179B2 (ja) 1994-07-05 2006-04-05 克寛 西野 運動・意識または言語障害の機能改善剤
DE19619510A1 (de) 1995-05-18 1996-11-21 Sumitomo Chemical Co Verfahren zur Herstellung von Threo-3-(3,4-dihydroxyphenyl)serin
JP3489319B2 (ja) 1996-03-12 2004-01-19 住友化学工業株式会社 カルボン酸誘導体、その製造法および用途
JPH115738A (ja) 1997-06-15 1999-01-12 Katsuhiro Nishino 脳虚血に伴う神経脱落症状の予防剤および超急性期治療剤
US6376531B1 (en) * 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
WO2005084330A2 (en) 2004-03-02 2005-09-15 Synergia Pharma, Inc. Compositions and methods for treating nasal congestion
USRE46555E1 (en) * 2006-02-17 2017-09-19 Teva Pharmaceuticals International Gmbh Deuterated catecholamine derivatives and medicaments comprising said compounds
JP2010520885A (ja) 2007-03-09 2010-06-17 チェルシー・セラピューティクス，インコーポレイテッド 線維筋痛症の治療のためのドロキシドパ及びその医薬組成物
EP2142185B1 (en) 2007-03-12 2012-08-15 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
US8383681B2 (en) 2007-05-07 2013-02-26 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders or attention deficit disorders
US7745665B2 (en) 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
US20100172916A1 (en) * 2008-11-10 2010-07-08 Auspex Pharmaceuticals, Inc. Substituted hydroxyphenylamine compounds
WO2010132128A1 (en) 2009-05-14 2010-11-18 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognitve functions in individuals with down syndrome and/or alzheimer's disease
EP2450343A4 (en) 2009-07-01 2013-01-09 Dainippon Sumitomo Pharma Co PROCESS FOR PREPARING THREO-3- (3,4-DIHYDROXYPHENYL) L-SERIN
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
US20130253061A1 (en) 2012-03-20 2013-09-26 Chelsea Therapeutics, Inc. Method of droxidopa synthesis

Also Published As

Publication number Publication date
EA201600093A1 (ru) 2016-08-31
IL266767A (en) 2019-07-31
EP3611159B1 (en) 2023-01-25
US20220072131A1 (en) 2022-03-10
SG11201510764QA (en) 2016-01-28
BR112016000338A2 (pt) 2017-08-22
HK1216747A1 (zh) 2016-12-02
CL2016000019A1 (es) 2016-11-04
KR20160041912A (ko) 2016-04-18
US20170319694A1 (en) 2017-11-09
BR112016000338A8 (pt) 2020-01-07
IL243488A0 (en) 2016-02-29
AU2018253594A1 (en) 2018-11-22
EP3611159A1 (en) 2020-02-19
EP3019467A4 (en) 2017-03-15
US20180280511A1 (en) 2018-10-04
CA2917159C (en) 2022-08-23
SG10201800166UA (en) 2018-02-27
HK1221713A1 (zh) 2017-06-09
EP3019467A1 (en) 2016-05-18
CN105473545A (zh) 2016-04-06
US20190374642A1 (en) 2019-12-12
WO2015006315A1 (en) 2015-01-15
JP6567515B2 (ja) 2019-08-28
US20150011630A1 (en) 2015-01-08
CN105473545B (zh) 2017-08-04
AU2014287418A1 (en) 2016-01-28
JP2016529228A (ja) 2016-09-23
CA2917159A1 (en) 2015-01-15
MX2016000219A (es) 2016-05-31

Similar Documents

Publication Publication Date Title
CU24309B1 (es) Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen
SV2018005791A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201800133A (es) Nuevos derivados piperidinilo sustituidos con (hetero) arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
SV2017005514A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
DOP2016000145A (es) Reguladores de nrf2
CR20150509A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
PE20160556A1 (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos
CR20150250A (es) Nuevos derivados de piridina
CU20170164A7 (es) Compuestos n-tieno (2,3-d)pirimidinil-d-fenilalanina, método para preparar los mismos y composiciones farmacéuticas que los contienen
SV2014004770A (es) Nuevos derivados de pirrol, su procedimiento de preparación y los composiciones farmacéuticas que los contienen
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
UY35469A (es) Moduladores de p2x7
SV2018005656A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina,un proceso para su preparacion y composiciones farmaceuticas que los contiene
ECSP13013074A (es) Nuevos derivados de piridina
CR20110610A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
CR20150447A (es) Nuevos derivados de pirazol
CR20160076A (es) NUEVOS DERIVADOS DE TRIAZOLO[4,5-d]PIRIMIDINA
CR20150204A (es) Nuevos derivados de piridina
SV2014004771A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20150440A (es) Nuevos derivados de piridina
UY35447A (es) Moduladores de p2x7
UY35410A (es) Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina
CR20150171A (es) Benzamidas
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
CR20130671A (es) Antagonistas de trpv4